USANA Q1 net sales $248M, EPS $0.95; raises FY23 guidance low end

USANA HEALTH SCIENCES INC

2023-Q1 EPS reported $0.95 revenue$248,360,000

Net sales $248M, +9% sequentially but -9% YoY; diluted EPS $0.95 (+44% sequentially, -17% YoY).
FY2023 guidance raised: net sales $875-$950M (previously $850-$950M), EPS $2.40-$3.30 (prev $2.35-$3.30).
Active customers 491,000, flat sequentially, -11% YoY; Asia Pacific net sales $200M (80% of total).
Q1 included ~$12M China COVID-demand benefit and ~$13M price-increase pull-forward; new market expansion planned.
Ended quarter with $295M cash, debt-free; no share repurchases; $83M remaining under authorization.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

USANA HEALTH SCIENCES INC reported the first quarter ended April 1, 2023 results: revenue $248 million, EPS $0.95. Guidance raised.

Period: the first quarter ended April 1, 2023
Revenue: $248 million
EPS: $0.95
Guidance: raised
Result: reported results

Exact text from the filing

First quarter net sales were $248 million versus $228 million for the fourth quarter of 2022 and $273 million during the first quarter of 2022. First quarter diluted EPS was $0.95 as compared with $0.66 for the fourth quarter of 2022 and $1.15 during the first quarter of 2022. Generated $13 million of operating cash flow during the quarter. Fiscal 2023 net sales and diluted EPS guidance updated to $875 to $950 million and $2.40 to $3.30, respectively, from $850 million to $950 million and $2.35 to $3.30.

View on SEC.gov

Browse all earnings releases →

USANA HEALTH SCIENCES INC filing history →

Source: SEC EDGAR

accession 0001157523-23-000608

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.